InvestorsHub Logo
Followers 6
Posts 1087
Boards Moderated 0
Alias Born 07/18/2006

Re: None

Wednesday, 05/18/2022 12:27:09 PM

Wednesday, May 18, 2022 12:27:09 PM

Post# of 17415
Time is Nephrons

It's a frustrating reality for me to know that a superior drug for LN is not being prescribed currently anywhere near it's potential- the lack of interest in Lupkynis is harming people.

Mary Crimmings, from the Lupus Foundation of America, said this today:
We know it takes an average of six years for a person to receive an accurate diagnosis of lupus. That's why reducing the time to diagnosis is a key priority for the Foundation. Awareness is also the first step to getting people diagnosed and treated sooner.

Aurinia says:
Evidence shows that even a single episode of LN can potentially shorten the life span of the kidneys by decades
https://www.timeisnephrons.com/

It took decades for Lupkynis to get FDA approval. It also easily cost more than the current market cap of Aurinia to get to this point.

It's an insane affront that this is the reality that Lupus Nephritis sufferers experience today.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News